CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Puretech Health PLC is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Puretech Health PLC
6 Tide Street, Suite 400
Phone: (617) 482-2333p:617 482-2333 Boston, MA  02210  United States Ticker: PRTCPRTC
Business Summary
PureTech Health plc is a clinical-stage company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company is engaged in the development of around 29 therapeutics and therapeutic candidates, including three that have been approved by the United States Food and Drug Administration. A number of these programs are advanced by the Company or its Founded Entities in various indications and stages of clinical development. Its primary programs include LYT-100 and LYT-200. Deupirfenidone (LYT-100) is being developed as a potential new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is an anti-galectin-9 monoclonal antibody (mAb) being developed for the treatment of hematological malignancies, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), as well as solid tumors, including head and neck cancers, with a focus on metastatic disease.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Lead Independent Non-Executive Chairman of the Board Raju S.Kucherlapati 81 6/20/2024
President, Director EricElenko 4/9/2024 4/9/2024
Chief Executive Officer, Director Bharatt M.Chowrira 60 4/9/2024 3/1/2017
7 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Gelesis Inc 501 Boylston St BOSTON MA United States
Gelesis Holdings Inc 501 Boylston Street, Suite 6102 BOSTON MA United States

Business Names
Business Name
Gelesis Inc
NeuroLex Laboratories, Inc.
PRTC
Vor BioPharma

General Information
Number of Employees: 56 (As of 12/31/2024)
Outstanding Shares: 240,189,449 (As of 2/28/2025)
Stock Exchange: LON
Federal Tax Id: 813305277
Fax Number: (617) 482-3337


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, June 5, 2025